

Special Issue

Advances in Pain Management: Exploring Molecular Mechanisms and Novel Therapies

Message from the Guest Editors

Pain is now recognized as a complex pathological state involving sophisticated interactions between peripheral sensory pathways, central nervous system processing, immune activation, and psychological factors. Over the past decade, there have been remarkable advancements in pain research, particularly in the areas of neuroinflammation, sensory signaling, and genetic susceptibility. This Special Issue provides an opportunity to bring together cutting-edge research that deepens our understanding of the molecular mechanisms underlying pain while also highlighting promising therapeutic approaches aimed at improving patient outcomes. Research areas may include, but are not limited to, the following:

- Molecular and cellular mechanisms of pain;
- Genetic and epigenetic factors in pain susceptibility and chronic pain conditions;
- Neuroimmune interactions in pain modulation;
- Emerging pharmacological targets for pain relief;
- Novel pain therapies, including gene therapy, stem cell therapy, and biologics;
- Innovative drug delivery systems for targeted pain relief.

We look forward to receiving your contributions and collaborating to advance the field of pain management.

Guest Editors

Dr. Christopher Robinson

Dr. Samuel Ang

Dr. Rodrigo Diez-Tafur

Deadline for manuscript submissions

31 January 2027



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/256022

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).